DataSheet1_Diabetes—Tuberculosis Care in Eswatini: A Qualitative Study of Opportunities and Recommendations for Effective Services Integration.PDF

Objective: This study describes the availability of basic services, equipment, and commodities for integrated DM–TB services, best practices by healthcare workers, and opportunities for better integration of DM–TB care in Eswatini.Methods: A qualitative design was used. Twenty-three healthcare workers participated in a survey and key informant interview.Results: Most respondents indicated DM and TB care are integrated and clients access blood pressure and fasting/random blood glucose assessment. Few respondents indicated they provide visual assessment, hearing assessment, and HbA1c testing. Respondents experienced stockouts of urinalysis strips, antihypertensive drugs, insulin, glucometer strips, and DM drugs in the previous 6 months before the interview. Four main themes emerged from the qualitative interviews—quality and current standards of care, best practices, opportunities, and recommendations to improve integrated services delivery.Conclusion: While DM care is provided for TB patients, the implementation of integrated DM–TB services is suboptimal as the quality and current standards of care vary across health facilities due to different patient-level and health system challenges. Some identified opportunities must be utilized for a successful DM–TB integration.</p

DataSheet2_Diabetes—Tuberculosis Care in Eswatini: A Qualitative Study of Opportunities and Recommendations for Effective Services Integration.PDF

Objective: This study describes the availability of basic services, equipment, and commodities for integrated DM–TB services, best practices by healthcare workers, and opportunities for better integration of DM–TB care in Eswatini.Methods: A qualitative design was used. Twenty-three healthcare workers participated in a survey and key informant interview.Results: Most respondents indicated DM and TB care are integrated and clients access blood pressure and fasting/random blood glucose assessment. Few respondents indicated they provide visual assessment, hearing assessment, and HbA1c testing. Respondents experienced stockouts of urinalysis strips, antihypertensive drugs, insulin, glucometer strips, and DM drugs in the previous 6 months before the interview. Four main themes emerged from the qualitative interviews—quality and current standards of care, best practices, opportunities, and recommendations to improve integrated services delivery.Conclusion: While DM care is provided for TB patients, the implementation of integrated DM–TB services is suboptimal as the quality and current standards of care vary across health facilities due to different patient-level and health system challenges. Some identified opportunities must be utilized for a successful DM–TB integration.</p

Change in NITs of liver steatosis and fibrosis from baseline.

Value at baseline for A: Median LFS of 0.60 for placebo and 0.63 for aleglitazar, B: Mean LAP of 69.5 for placebo and 67.8 for aleglitazar, C: Mean FIB-4 of 1.40 for placebo and 1.44 for aleglitazar, D: Mean NFS of -0.50 for placebo and -0.41 for aleglitazar. Error bars indicate 95% CIs. Change from baseline is significantly different in the aleglitazar and the placebo group at all timepoints ≥3 mohs for all proxies (all P<0.001).</p

Change in FIB-4 and NFS category from baseline until 24 months follow-up.

Proportion of randomized patients that either improved (changed to a lower category), worsened (changed to a higher category) or did not change in category. Proportion of change is significantly different between treatment and placebo for FIB-4 (A) and NFS (B). FIB-4: Both improvement and worsening PPP = 0.024.</p

Changes in absolute values of non-invasive tests over time.

Changes in absolute values of non-invasive tests over time.</p

Baseline characteristics of the patients in the aleglitazar group compared with the placebo group.

Baseline characteristics of the patients in the aleglitazar group compared with the placebo group.</p

Change in AST/ALT ratio and BMI from baseline.

Value at baseline for A: Mean AST/ALT of 1.21 for placebo and 1.22 for aleglitazar, B: Mean BMI of 29.5 kg/m2 for placebo and 29.3 kg/m2 for aleglitazar. Error bars indicate 95% CIs. Change from baseline is significantly different in the aleglitazar and the placebo group at all timepoints ≥1 month for both AST/ALT ratio and BMI (all P<0.001).</p

Additional file 1 of A cross-sectional survey on the early impact of COVID-19 on the uptake of decentralised trial methods in the conduct of clinical trials

Additional file 1

International Classification of Primary Care (ICPC) codes included in general practitioner (GP) diagnosed infections.

International Classification of Primary Care (ICPC) codes included in general practitioner (GP) diagnosed infections.</p

Updated framework for interpersonal communication in MNC, based on Feldman-Stewart and Brundage [14].

Updated framework for interpersonal communication in MNC, based on Feldman-Stewart and Brundage [14].</p